
Sesen Bio Investor Relations Material
Latest events

Investor Update
Sesen Bio

Q4 2023
1 Apr, 2024

Q4 2022
28 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sesen Bio Inc
Access all reports
Sesen Bio is developing fusion protein therapeutics for the treatment of patients with cancer based on a proprietary platform technology. This technology utilizes proprietary ligand design, a data-driven computational approach to molecular modeling, and molecular engineering to develop a library of novel fusion protein therapeutics. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SESN
Country
🇺🇸 United States